Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Sarah, Kernaghan"'
Autor:
Sharon B. Love, Fay Cafferty, Claire Snowdon, Karen Carty, Joshua Savage, Philip Pallmann, Lucy McParland, Louise Brown, Lindsey Masters, Francesca Schiavone, Dominic Hague, Stephen Townsend, Claire Amos, Annabelle South, Kate Sturgeon, Ruth Langley, Timothy Maughan, Nicholas James, Emma Hall, Sarah Kernaghan, Judith Bliss, Nick Turner, Andrew Tutt, Christina Yap, Charlotte Firth, Anthony Kong, Hisham Mehanna, Colin Watts, Robert Hills, Ian Thomas, Mhairi Copland, Sue Bell, David Sebag-Montefiore, Robert Jones, Mahesh K. B. Parmar, Matthew R. Sydes
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-14 (2022)
Abstract Background Late-phase platform protocols (including basket, umbrella, multi-arm multi-stage (MAMS), and master protocols) are generally agreed to be more efficient than traditional two-arm clinical trial designs but are not extensively used.
Externí odkaz:
https://doaj.org/article/f16f51eff76c45b9b2545597e35df8a3
Autor:
Claire Snowdon, Sarah Kernaghan, Laura Moretti, Nicholas C. Turner, Alistair Ring, Katie Wilkinson, Sue Martin, Stephanie Foster, Lucy S. Kilburn, Judith M. Bliss
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-10 (2022)
Abstract Background Platform trial designs are used increasingly in cancer clinical research and are considered an efficient model for evaluating multiple compounds within a single disease or disease subtype. However, these trial designs can be chall
Externí odkaz:
https://doaj.org/article/95aec4e90bb041c8a063405e0216014f
Autor:
Belinda Kingston, Rosalind J. Cutts, Hannah Bye, Matthew Beaney, Giselle Walsh-Crestani, Sarah Hrebien, Claire Swift, Lucy S. Kilburn, Sarah Kernaghan, Laura Moretti, Katie Wilkinson, Andrew M. Wardley, Iain R. Macpherson, Richard D. Baird, Rebecca Roylance, Jorge S. Reis-Filho, Michael Hubank, Iris Faull, Kimberly C. Banks, Richard B. Lanman, Isaac Garcia-Murillas, Judith M. Bliss, Alistair Ring, Nicholas C. Turner
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Circulating tumour DNA can provide useful information on disease burden. Here, the authors analysed circulating tumour DNA from 800 patients from a breast cancer clinical trial and investigate the subclonal nature of the disease, and identify DNA mut
Externí odkaz:
https://doaj.org/article/5f176e5d5bcb4792adb4ec1effb35966
Autor:
Belinda Kingston, Rosalind J. Cutts, Hannah Bye, Matthew Beaney, Giselle Walsh-Crestani, Sarah Hrebien, Claire Swift, Lucy S. Kilburn, Sarah Kernaghan, Laura Moretti, Katie Wilkinson, Andrew M. Wardley, Iain R. Macpherson, Richard D. Baird, Rebecca Roylance, Jorge S. Reis-Filho, Michael Hubank, Iris Faull, Kimberly C. Banks, Richard B. Lanman, Isaac Garcia-Murillas, Judith M. Bliss, Alistair Ring, Nicholas C. Turner
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-1 (2021)
Externí odkaz:
https://doaj.org/article/c4a8fb81f49749e99d11db28fb611c64
Publikováno v:
Trials, Vol 18, Iss 1, Pp 1-4 (2017)
Abstract Background Academic clinical trials play a fundamental role in the development of new treatments, the repurposing of existing treatments and in addressing areas of unmet clinical need. With cancer treatments increasingly targeted at molecula
Externí odkaz:
https://doaj.org/article/5784b2f9d731464a962f0e8ae1ecc704
Autor:
Nicholas Turner, Claire Swift, Ben Jenkins, Lucy Kilburn, Maria Coakley, Matthew Beaney, Lisa Fox, Katie Goddard, Isaac Garcia-Murillas, Peter Hall, Catherine Harper-Wynne, Tamas Hickish, Sarah Kernaghan, Iain Macpherson, Alicia Okines, Carlo Palmieri, Sophie Perry, Katrina Randle, Claire Snowdon, Hilary Stobart, Andrew Wardley, Duncan Wheatley, Simon Waters, Matthew Winter, Judith Bliss
Publikováno v:
Cancer Research. 82:GS3-06
Background Detection of circulating tumour DNA (ctDNA) in patients (pts) who have completed treatment for early-stage triple negative breast cancer (TNBC) is associated with a very high risk of future relapse. Identifiying those at high risk of subse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c87025dfbe68a40c7a5f74097df5e6c8
https://doi.org/10.1158/1538-7445.sabcs21-gs3-06
https://doi.org/10.1158/1538-7445.sabcs21-gs3-06
Autor:
Iain Macpherson, Stuart McIntosh, Lucy Kilburn, Holly Tovey, Sarah Kernaghan, Katie Goddard, Indrani Bhattacharya, Clinton Boyd, Charlotte Coles, Cliona Kirwan, Mairead Mackenzie, Ciara O’Brien, Alistair Ring, Claire Snowdon, Hilary Stobart, Duncan Wheatley, Andrew Wardley, Abeer Shaaban, Peter Hall, David Cameron, Judith Bliss
Publikováno v:
Cancer Research. 82:OT2-05
Background The presence or absence of residual disease following neoadjuvant systemic anti-cancer therapy (neoSACT) for HER2-positive early breast cancer (HER2+ EBC) provides powerful prognostic information that may guide subsequent adjuvant treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a21cd1f2ba7e31cfd59954e7383a662
https://doi.org/10.1158/1538-7445.sabcs21-ot2-05-01
https://doi.org/10.1158/1538-7445.sabcs21-ot2-05-01
Autor:
Holly Tovey, Orsolya Sipos, Katherine A Hoadley, Joel S Parker, Jelmar Quist, Sarah Kernaghan, Lucy Kilburn, Roberto Salgado, Sherene Loi, Richard D Kennedy, Ioannis Roxanis, Patrycja Gazinska, Sarah E. Pinder, Judith Bliss, Charles M. Perou, Syed Haider, Andrew Tutt, Anita Grigoriadis, Maggie Chon U Cheang
Publikováno v:
Cancer Research. 83:PD9-06
Background The TNT trial (NCT00532727) showed no evidence of carboplatin (C) superiority over docetaxel (D) overall in metastatic triple negative breast cancers (TNBC), but a C benefit was observed in the pre-specified sub-group analysis in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa5543bcf8ec4daceca950de6d8be7c9
https://doi.org/10.1158/1538-7445.sabcs22-pd9-06
https://doi.org/10.1158/1538-7445.sabcs22-pd9-06
Autor:
Cheryl Gillett, C. Toms, Julie Owen, Sarah Kernaghan, Holly Tovey, Andrew Tutt, Patrycja Gazinska, Judith M Bliss, Sarah Maguire, Sabine C. Linn, Maggie C.U. Cheang, Orsolya Sipos, Sarah E Pinder, Salpie Nowinski, Syed Haider, Nick Orr, Anita Grigoriadis, Jelmar Quist
Publikováno v:
Sipos, O, Tovey, H, Quist, J, Hyder, S, Nowinski, S, Gazinska, P, Kernaghan, S, Toms, C, Maguire, S, Orr, N, Linn, S, Owen, J, Gillett, C, Pinder, S, Bliss, J, Tutt, A, Cheang, M C U & Grigoriadis, A 2021, ' Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer : the TNT trial ', Annals of Oncology, vol. 32, no. 1, pp. 58-65 . https://doi.org/10.1016/j.annonc.2020.10.475
Annals of Oncology
Annals of Oncology
Background In the TNT trial of triple negative breast cancer (NCT00532727), germline BRCA1/2 mutations were present in 28% of carboplatin responders. We assessed quantitative measures of structural chromosomal instability (CIN) to identify a wider pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28e6cd1cee23bb68298d62eef6fcf5bf
https://doi.org/10.1016/j.annonc.2020.10.475
https://doi.org/10.1016/j.annonc.2020.10.475
Autor:
Matthew C Winter, Daniel Rea, Jacinta Abraham, Olga Oikonomidou, Iain R. Macpherson, David Cameron, Jeremy P Braybrooke, Sarah Kernaghan, Andrew M Wardley, Heidrun Gevensleben, Laura Moretti, Mark Tuthill, Katrina Randle, Peter Stephens, A Ring, Mike Hubank, Judith M Bliss, Rebecca Roylance, Abeer M Shaaban, Hannah Bye, Lucy Kilburn, Sue Martin, B Kingston, Katie Wilkinson, Nicholas C. Turner, Claire Snowdon, Ros Cutts, Richard D. Baird
Publikováno v:
C Turner, N, Kingston, B, S Kilburn, L, Kernaghan, S, M Wardley, A, R Macpherson, I, D Baird, R, Roylance, R, Stephens, P, Oikonomidou, O, P Braybrooke, J, Tuthill, M, Abraham, J, C Winter, M, Bye, H, Hubank, M, Gevensleben, H, Cutts, R, Snowdon, C, Rea, D, Cameron, D A, Shaaban, A, Randle, K, Martin, S, Wilkinson, K, Moretti, L, Bliss, J M & Ring, A 2020, ' Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial ', The Lancet Oncology, vol. 21, no. 10, pp. 1296-1308 . https://doi.org/10.1016/S1470-2045(20)30444-7
BACKGROUND: Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the accuracy of ctDNA testing in advanced breast cancer and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07a5a7ae2a2af9e5ba7c16e614105e61
https://doi.org/10.1016/s1470-2045(20)30444-7
https://doi.org/10.1016/s1470-2045(20)30444-7